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Endothelial progenitor cells (EPCs) have an important role in the maintenance of
vascular integrity and homeostasis. While there are many studies that explain EPCs
mechanisms action, there are few studies that demonstrate how they interact with other
emerging physiological elements such as Endothelial Microparticles (EMPs). EMPs are
membranous structures with a size between 100 and 1000 nm that act as molecular
information transporter in biological systems and are known as an important elements
in develop different pathologies; moreover a lot of works explains that are novel
biomarkers. To elucidate these interactions, we proposed an in vitromodel of endothelial
damage mediated by TNFalpha, in which damaged EMPs and EPCs are in contact to
assess EPCs functional effects. We have observed that damaged EMPs can modulate
several EPCs classic factors as colony forming units (CFUs), contribution to repair a
physically damaged endothelium (wound healing), binding to mature endothelium, and
co-adjuvants to the formation of new vessels in vitro (angiogenesis). All of these in a
dose-dependent manner. Damaged EMPs at a concentration of 103 MPs/ml have an
activating effect of these capabilities, while at concentrations of 105 MPs/ml these effects
are attenuated or reduced. This in vitromodel helps explain that in diseases where there is
an imbalance between these two elements (EPCs and damaged EMPs), the key cellular
elements in the regeneration and maintenance of vascular homeostasis (EPCs) are not
fully functional, and could explain, at least in part, endothelial dysfunction associated in
various pathologies.
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INTRODUCTION
Several studies have shown that most damaged cells produce and release microparticles (MPs) and
act as signaling factors that elicit a coordinated cellular response to the injury (Soriano et al., 2014).
These MPs are membranous bodies ranging from 0.2 to 1µm in size and are present in different
biological fluids. The quantification of these particles in plasma could be used as a diagnostic tool
because pathological conditions often result in an increased number ofMPs due to poor endothelial
cell function (Diehl et al., 2008).
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There is a physiological mechanism responsible for the repair
of the endothelium to prevent the loss of its integrity produced
by vascular disease (Shantsila et al., 2007). This repair process
involves the recruitment of endothelial progenitor cells (EPCs)
from the bone marrow. A correlation has previously been found
between the numbers of MPs and EPCs in the peripheral
blood (Burger and Touyz, 2012). Initially, the proliferation
and migration of adjacent endothelial cells had been identified
as the endothelial repair factor; subsequent studies described
a mechanism for endothelial structure maintenance that was
associated with the capacity of circulating EPCs to differentiate
and repair the damaged endothelial tissue (Asahara et al., 1997).
This mechanism is supported by the fact that dysfunction of
the endothelium is associated with compromised EPC function
(Peng et al., 2015).
Due to the importance of this endothelial damage-repair
mechanism in the maintenance of vascular homeostasis, it is
logical to think the existence of a close communication between
the damaged endothelial cells and EPCs. What these signals may
be and when they are activated have not yet been elucidated and
could involve several factors (Deregibus et al., 2007).
Previous studies performed by our group indicate that plasma
MPs, in both healthy controls and chronic kidney disease,
stimulate the activity of EPCs (Soriano et al., 2014). However,
we do not know whether this effect is due to the activity of
all circulating MPs or is specific to endothelial MPs (EMPs).
Therefore, it is important to transfer these results to an in vitro
endothelial model in which the only factor utilized is derived
from the endothelium.
Despite the previously described findings, we have not been
able to find other studies that analyzed whether damaged
endothelial cells and subsequent EMP production are capable
of modulating the repair activity promoted by EPCs; we
believe that this question must be addressed to improve
our knowledge of the physiological mechanisms involved in
maintaining endothelial integrity. Therefore, we performed this
study to determine the EMP production capacity of a damaged
endothelial cell model and whether these EMPs are able to
stimulate the functional activity of EPCs in a dose-dependent
manner.
MATERIALS AND METHODS
Human Umbilical Vein Endothelial Cell
Culture
Human umbilical vein endothelial cells (HUVECs) were
obtained from Cell Systems (Clonetics, Solingen, Germany)
and cultured at 37◦C in a 5% CO2 atmosphere in standard
endothelial cell basal medium (EBM, CAMBREX Bios Science,
Walkersville, Inc., Walkersville, MD, USA) plus endothelial cell-
growth medium supplements (EGM, CAMBREX) and 10% fetal
calf serum (FCS, Invitrogen; Molecular probes, Eugene, OR,
USA). First-passage cryopreserved HUVECs were grown and
serially passaged; the number of population doublings (PDs)
was calculated using the formula PD = (ln [number of cells
harvested]–ln [number of cells seeded])/ln2.
To stimulate HUVECs, the cells were cultured for 24 h at each
passage with tumor necrosis factor alpha (TNFalpha, SIGMA-
ALDRICH), 10 ng/ml. The optimal concentration and time of
culture with TNFalpha were based on preliminary studies from
concentration and time-dependence studies (Majewska et al.,
1997).
Endothelial Activation By TNFalpha
Cells were treated with 10 ng/ml TNFalpha (Majewska et al.,
1997) for various incubation times (24, 48, and 72 h).
The cells were harvested by mechanical disruption and
separated by centrifugation. After washing twice with sterile
phosphate buffered saline (PBS), the cells were labeled with
Monoclonal antibodies (mAbs) against PECAM [phycoerythrin
(PE)-labeled mAb, CD106, BD Pharmingen™, ref555647] and
ICAM [fluorescein 5′-isothiocyanate (FITC)-labeledmAb, CD54,
Invitrogen, ref MHCD5401] for 20min in the dark. Apoptosis
was evaluated by the percentage of annexin V+/PI+ (Propidium
Iodide) cells. Endothelial cell proliferation was quantified by
the expression of proliferating cell nuclear antigen (PCNA)
(FITC-labeled mouse anti-human PCNA, BD Pharmingen™, ref
556030) according to the manufacturer’s instructions. Analysis of
adhesion markers, proliferation and apoptosis were performed
via flow cytometry (Accuri C6, BD Biosciences, USA).
MPs Isolation and Quantification
The supernatant of TNFalpha-treated (10 ng/ml) HUVECs was
collected at 24 h and centrifuged at low speed (2500 rpm,
10min, 4◦C) to eliminate cell debris. Then, the supernatant
was centrifuged several times at 13000 rpm at 4◦C for 10min
to concentrate the MPs. The supernatant were not discarded,
to produce EMP-Free supernatant. Flow cytometry (Accuri C6
flow cytometer, Becton Dickinson, USA) was used to determine
the quantity of MPs secreted by the endothelial cells in the
presence of TNFalpha at 24 h. As an internal reference for size
and complexity, 1-µm diameters Flow-Count Fluoro-spheres
(Beckmann Coulter) were used. In addition, the MP population
was restricted by size [forward-scatter area (FSC-A) 105.5–106]
and complexity [side-scatter area (SSC-A) 104–106]. Afterward,
direct relationships were used to determine the volumes required
to treat the EPC culture (103 and 105MPs/ml).
MP Distribution on Endothelial Cells
EMPs suspended in 60µl of PBS were labeled with 2µl of Cell
Tracker™ CM-DiI (Molecular Probes, Life Technologies, USA)
for 2 h at 37◦C in darkness. The EMPs were then washed two
times in sterile PBS (2× 10,000 g, 4◦C) to remove excess probe.
Finally, the labeled and washed EMPs were again suspended in
60µL of sterile PBS and distributed to HUVEC cultures.
HUVECs (104 cells/glass coverslip) were treated with labeled
MPs for 24 h to visualize the microparticles on endothelial cells.
The cells were then fixed with 2% paraformaldehyde for 10min,
permeabilized with 0.1% (v/v) Triton X-100 in PBS for 10min,
washed with PBS, blocked with 4% bovine serum albumin (BSA)
for 1 h at room temperature and incubated overnight at 4◦C with
anti-phalloidin Ab (1:200 dilution). Next, the cells were incubated
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at 37◦C with α-mouse-Alexa-Fluor R© 633 (1:2000) and α-rabbit-
Alexa-Fluor R© 488 (1:2000) for 1 h in the dark. The coverslips
were washed and mounted with ProLong Gold antifade reagent
with 4′-6-diamidino-2-phenylindole (DAPI) (Invitrogen Eugene,
Oregon). Detection was performed by confocal laser scanning
microscopy (LEICA TCS-SL, Heidelberg, Germany).
EPC Culture
Peripheral blood mononuclear cells from healthy donors
were isolated by density gradient centrifugation (Lymphoprep,
Axis-Shield PoC, Oslo, Norway), washed with PBS (GIBCO,
Invitrogen, Carlsbad, CA) plus 20% FBS, and suspended in
endothelial cell basal medium-2 (EBM-2) (Lonza, Allendale,
NJ, USA) supplemented with single aliquots of endothelial cell
growth medium (EGM-2) (VEGF, human EGF-B, recombinant
IGF-1, human EGF, heparin, ascorbic acid, and GA-100, Lonza)
and 15% autologous plasma. Mononuclear cells were plated onto
fibronectin (Biocoat, BD Biosciences, Franklin Lakes, NJ, USA)
in coated, six-well plates at a density of 5 × 106 cells/well.
We then incubated the fibronectin-coated plates at 37◦C in
a 5% CO2 atmosphere; 4 days later, we removed the cells in
suspension, and the fraction of attached cells was cultivated with
EBM-2 supplemented with 15% autologous plasma. The medium
was recharged every 2 days for 3–4 weeks. After this period,
EPCs could be visualized with an optical microscope (OPTIKA
Microscopes, Italy) in the form of colonies (colony forming units,
CFUs). The EPC phenotype (CD34+CD133+VEGFR2+) was
verified with a cellular purity of>90%.
EPC Proliferation Activity—Use of Various
Doses of MPs Obtained From Endothelial
Cultures Treated With TNFalpha For 24 h
EPCs enriched from cultures obtained with themethod described
in the previous section were used for treatment with different
concentration of MPs from TNFalpha-treated HUVECs. On 7th
day EPCs cultures, the two different concentrations of MPs (103
and 105MPs/ml) were added. The medium and the two different
stimuli were renewed every 2 days until the EPCs culture end
(28th day). On day 28, the number of adherent cell colonies
was counted by 3 observers using an inverted fluorescence
microscope (OPTIKA Microscopes, Italy) in 10 random high-
power fields.
Wound Assay
To evaluate the wound healing capacity of the treated EPCs in
a mature endothelial cell monolayer, we inflicted a wound by
physical damage perpendicular to the well axis when the cells
were at 70–80% confluence. Afterward, 15000 treated EPCs were
added to the wounded endothelial cell monolayer, and the healing
process was monitored over 2-h periods until reaching 24 h. At
24 h, we observed the extent of wound healing with regard to
the EPCs treated with 103MPs/ml. At the indicated intervals,
photographs were taken with an optical inverted microscope
(OPTIKA Microscopes, Italy), and the images were analyzed
using the included software (Optika Vision Pro, Italy); the
percentage of the closed area compared with the initial wound
area was quantified.
EPC Adhesion over a HUVEC Monolayer
To observe the magnitude to which MP-treated EPCs can
adhere to an endothelial monolayer, EPCs were harvested by
mechanical disruption with a mini-scrapper, and labeled with
Cell Tracker™ CM-DiI (Molecular Probes, Life Technologies,
USA) at 37◦C for 2 h in the dark and in appropriated medium
(EBM-2, Lonza, USA) which enabled the detection of the
EPCs on an endothelial cell monolayer via fluorescence. For
this purpose, EPC cells that were treated with different doses
of TNFalpha MPs and previously labeled with Cell Tracker™
CM-DiI were added (50,000/well) to 6-position culture plates
containing endothelial cells at 70–80% confluence, and the
co-cultures were stabilized for 24 h. The number of adherent
fluorescent EPCs in 10 random high-power fields was quantified
using IMAGEj (Eclipse Ti-S, Nikon Instruments Europe B.V.,
Badhoevedorp, The Netherlands). The quantification is related
to the randomized number of fluorescent pixels.
Angiogenesis Assay in Matrigel
To evaluate the effect of treated EPCs on endothelial cells,
angiogenesis experiments were designed in 15-well plates (IBIDI)
coated with 10µl of Matrigel (Corning). For the angiogenesis
assay, a total of 2500 cells/well were plated, of which 50% were
EPCs obtained from MP-treated cultures, and the remaining
50% were mature endothelial cells (HUVECs) at low passage
stages (3–4), with their respective treatments, as well as an
internal positive control, VEGF (50 ng/ml). The formation of
vascular structures was monitored over a period of 2–3 h.
Once this period had elapsed, photographs were taken with an
optical inverted microscope (Optika microscopia, Italy), and an
automated analysis was performed with the IMAGEj software.
Two parameters were taken for the quantification experiments
(total master segments length and NB master junctions).
Statistical Analysis
Each sample was analyzed in triplicate, and each experiment
was performed at least three times. The data are presented
as the means± SD, and analysis of variance (ANOVA) with a
Bonferroni post-hoc correction was applied for the statistical
analysis. The visual counts via microscopy were performed by
three independent researchers. The statistical analyses and the
creation of images were performed using the program Graph Pad
Prism 5.0.
RESULTS
TNFalpha Induces Endothelial Damage
after 48h of Treatment
We determined the extent of the damage produced by the
pro-inflammatory cytokine TNFalpha. For this purpose, we
started with a concentration known to modulate the expression
of adhesion molecules (Majewska et al., 1997) and evaluated
different treatment times to determine when the endothelial
cells are activated without leading to cell damage. We observed
that after 24 h of TNFalpha treatment, there is a significant
increase in the mean fluorescence channel (MFC) for the ICAM1
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FIGURE 1 | (A) ICAM expression obtained by flow cytometry of HUVECs treated with 10 ng/ml TNFalpha at different time points. The expression is quantified by
changes in the mean fluorescent channel (MFC). (B) PECAM expression obtained by flow cytometry on HUVECS treated with 10 ng/ml TNFalpha at different time
points. Expression units are similar to ICAM (MFC). (C) Differences in total numbers of annexin V+/IP+ cells (late apoptosis) observed via flow cytometry in cultures
treated with TNFalpha at different time points. These values are compared with the control culture, in which the number of apoptotic cells is set to 1. (D) Decrease in
the number of PCNA+ cells (proliferating cells) in cultures treated with TNFalpha at different time points. *vs. control, #vs. TNFalpha 24 h, § vs. TNFalpha 48 h.
**p < 0.05; ***p < 0.001.
molecule compared to 0 h (550.30± 35.61 vs. 378.90± 28.82;
p < 0.05) (Figure 1). In a similar manner, the MFC for the
PECAM molecule increases significantly at 24 h (196.2± 9.2 vs.
151.9± 3.17; p < 0.05) (Figure 1). At 48 h of treatment with
TNFalpha, there is amore acute increase in theMFC for these two
membrane molecules (Figure 1). However, at 72 h of treatment,
the MFC for both markers decreases compared with 24 and 48 h.
The quantity of apoptotic cells undergoes a slight increase
after 24 h of culture (1.7± 0.2 vs. 1 “n-fold”; p = 0.4). This
increment is high and statistically significant at 48 and 72 h. Last,
cell proliferation decreases over time in response to TNFalpha,
such that at 24 h there is a significant decrease in the number
of proliferating cells. Moreover, as the culture advances, the
quantity of proliferating cells diminishes to levels of 22% at 72 h
(Figure 1).
Considering all of these time-response data, we chose use the
MPs obtained from the TNFalpha treated endothelial cells at 24 h
because there are signs of activation but not of cellular damage,
which would be observed at other times (48 and 72 h).
Endothelial Cells Release a Higher Number
of MPs in the Presence of TNFalpha at 24h
We observed that the supernatants obtained after 24 h in culture
have a significantly higher number ofMPs/µl than those obtained
from cells at the baseline state (156.44± 3.41 vs. 12.20± 0.86
MPs/µl; p < 0.001) (Figure 2). Moreover, we determined that
these MPs are structures that transport information between
HUVEC cells because we observed an incorporation of these
MPs in 4–9 total cells/field on confocal microscopy images. Last,
we also observed that the MPs are able to attain a perinuclear
position (Figure 2).
MPs from Activated Endothelial Cells
Modulate the In vitro Progression of EPC
Cultures
We observed that MPs obtained from endothelial cell cultures
activated with TNFalpha for 24 h are capable of modulating
the in vitro behavior of EPCs. After 7 days of culture, and
after discarding cells that is not going to differentiate EPCs, a
quantification of the number of cells per well was performed.
The purification efficiency of cells obtained was 163,685± 12365
cells/well. These culture wells were treated with the two
different doses of MPs (103MPs/ml and 105MPs/ml), in a total
volume of 2ml culture medium. The ratio obtained in the
condition 103MPs/ml was 0.0123± 0.001 (<2: 100MPs/cell) and
when using 105MPs/ml a ratio of 1.231± 0.02 was obtained
(>1:1MPs/cell) (Figure 3A).
After the end of the EPCs cultures (28th day) and when the
EPCs are in contact with a concentration of 103MPs/ml, there
is a significant increase in the number of CFUs compared with
the control EPCs (8.880± 1.22 vs. 6.000± 0.50 CFUs/field; p <
0.05). To disprove whether this proliferative effect is due to other
molecules, the cells were treated with an MP-free supernatant,
and we observed no increase in CFU number (5.896± 0.5 vs.
6.000± 0.5 CFUs/field; p = 0.7). In contrast, if EPCs were
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FIGURE 2 | (A) Diagram of flow cytometry events that indicates the events corresponding to EMPs isolated from supernatants of HUVEC cultures treated with
TNFalpha at 24 h (right) and control HUVECs (left). The MP population separated from background noise by manual gating, using 1-µm diameter fluorescent
microspheres as a reference (circled). The X axis represents size (FSC-A), whereas the Y axis represents complexity (SSC-A), both in Log units. (B) Representative
histogram of the quantity of isolated MPs secreted under these two conditions (control vs. TNFalpha 24 h). ***p < 0.001 vs. Control. (C) Confocal microscopy image at
24 h of HUVEC culture with 105MPs/ml. The MPs can be observed (marked in red with CellTrackerTM CM-DiI) as accepted by the recipient cell, preferentially
distributed within a perinuclear position.
treated with the MPs from activated cells but at a different
concentration (105MPs/ml), we observed a mechanism contrary
to that described with 103MPs/ml; there was a significant
decrease in the number of CFUs compared to the control
(2.194± 0.36 vs. 6.000± 0.50 CFUs/field; p < 0.05). Finally,
we observed that in EPCs cultures in the presence of TNFalpha
(10 ng/ml), CFU formation by the EPCs could not be detected
(Figure 3B).
EPCs Treated with MPs from Activated
Endothelial Cells Are Involved in Wound
Healing Progression in an Endothelial Cell
Monolayer
EPCs treated with TNFMPs (103MPs/ml) ledmature endothelial
cells to close the wound at the same rate as the control cells.
However, those EPCs treated with the highest dose of MPs
(105MPs/ml) delayed wound healing, leaving behind a cell free
zone in the inflicted wound corresponding to 21% of the total
initial wound area (Figure 4). The open area remaining at 24 h
in mature endothelial cells in contact with EPCs treated with
high MP doses (105MPs/ml) is significantly larger than that
left behind from EPCs treated with low MP doses (103MPs/ml)
(341.998± 88.779µm2 vs. 115.184± 22.766µm2, respectively;
p = 0.001) (Figure 4).
EPCs Treated with MPs from Activated
Endothelial Cells have Different Adhesion
Capabilities on an Endothelial Cell
Monolayer
We observed that the adhesion capacity of EPCs treated with
a low MP doses (103MPs/ml) over 24 h is significantly higher
than that of EPCs treated with a high doses of MPs (105MPs/ml)
(10.028± 2.80 vs. 95.400± 26.60 FU/field; p < 0.001) (Figure 5).
Moreover, to corroborate the absence of any factor other
than MPs, we cultivated the EPCs with MP-free supernatants
and observed that the adhesion capacity of these cells was
slightly higher than that of the control EPCs (1599± 721. vs.
643.354± 189.1 FU/field; p = 0.4). The EPCs treated with higher
doses had lower adhesion capacity under all conditions, even
presenting a lower adhesion tendency when compared with the
control EPCs (95.40± 26.6 FU/field vs. all conditions; p < 0.001)
(Figure 5).
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FIGURE 3 | (A) Histogram of different ratios obtained after the MPS treatments in 7th day of EPCs cultures; ***vs. Control p < 0.001. (B) Optical inverted microscopy
images (40×) of CFUs in EPC cultures at 25 days of culture with EMPs from TNFalpha-treated HUVECs at different concentrations. (C) Histogram of CFUs by field
under different experimental conditions. It can be observed how TNFalpha treatment results in CFUs. *vs. Control and FREE-EMPs, p < 0.05; **vs. Control,
FREE-EMPs, 103EMP/ml, p < 0.001.
Pro/Anti-Angiogenic Effects of MP-Treated
EPCs on Mature Endothelial Cells
We evaluated the capacity of EPCs to induce angiogenesis in
mature endothelial cells, and observed their capacity to stimulate
angiogenesis when the EPCs were treated with a low MP dose
(103MPs/ml) compared with the control (17,749± 1505µm
vs. 12024± 456µm p < 0.05). However, we observed that
EPCs treated with a high dose of MPs (105MPs/ml) lose some
of this capacity, such that mature endothelial cells form a
significantly lower number of vascular vessels in the 3D matrix
for angiogenesis (7913± 499µm vs. 12024± 456µm; p < 0.05)
(Figure 6). Moreover, we also confirmed that this mechanism
is dependent on the treatment of the EPCs with MPs because
those EPCs treated with MP-free supernatants behave similar
to the control EPCs (10834± 689µm vs. 12024± 456µm; p =
0.35). Last, it must be highlighted that the induction of vascular
vessel formation in mature endothelial cells via EPCs treated
with 103MPs/ml produces 55% of the total capacity of these
cells regarding the formation of vessels in the presence of VEGF
(Figure 6).
DISCUSSION
Vascular endothelial cells are constantly exposed to factors such
as cytokines (Mackay et al., 1993) or different toxins (Dou
et al., 2002) circulating in the bloodstream that may provoke
endothelial cell damage or death (Liu et al., 2015); therefore,
there is a physiological turnover mechanism for endothelial
cells mainly associated with the activation and differentiation of
progenitor endothelial cells (Zhang et al., 2014b). In this study we
show how EPCs proliferate, differentiate and acquire the capacity
to bind to endothelial cells in response to stimulation by MPs
produced by TNFalpha-activated endothelial cells.
Damage produced by TNFalpha to mature endothelial cells
is reflected in the higher expression of endothelial cell adhesion
markers (ICAM, PECAM) (Swerlick et al., 1992). At 72 h, a
decrease in the MFC can be observed for these membrane
proteins, which could be explained by the greater number of
apoptotic cells and lower number of proliferating cells at this
time point, which represent additional impacts of the long-
term damage induced by TNFalpha (Deshpande et al., 2000).
A lot of works demonstrate that TNFalpha is a good stimulus
to activate endothelial cells (Zhou-Stache et al., 2002). There
are a great variety of signaling pathway of TNFalpha treated
cells (Yan et al., 2011). Moreover, some works propose that
the endothelial activation by TNFalpha increase the release of
microRNAs loading microparticles (Zhang et al., 2014a). In our
model, we observed that there is a time that was considered as
activation time (24 h). In this point, the microparticles released
were used to modify EPCs culture in a dose-dependent manner.
Regarding the expression of EMPs in culture, we observed
that the event/µl density assessed by the flow cytometer is higher
than under baseline conditions, which leads us to suggest that
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FIGURE 4 | Wound healing assay in mature HUVECs in the presence of treated EPCs. (A) Area free of cells after 24 h of physical damage to the culture. (B) %
area closed with respect to the time in which the wound was healing, after contact with treated EPCs on the HUVEC monolayer. (C) Representative images at initial
time (upper row) and at the final time point of 24 h (lower row) of wound healing by HUVECs in contact with EPCs treated with concentrations of EMPs from the
TNFalpha treatments (40×). **p < 0.05 vs. Control and 103MP/ml; #p < 0.001 vs. Control and 105MP/ml.
FIGURE 5 | (A) Representative inverted microscopy images of the HUVEC monolayer and the adhesion of EPCs treated with different doses of MPs from the
TNFalpha cultures, merging the images from the bright field and fluorescence filter for CellTrackerTM CM-DiI (40×). (B) Representative histogram of fluorescent units
obtained per field at different endothelial cells plus treated EPCs co-culture conditions. **p < 0.001 vs. Control, free-EMPs and 105MPs/ml.
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FIGURE 6 | (A) (Left) Histogram of the obtained values for the quantification total master segments length parameter for angiogenesis; (right) for another parameter
defined as the NB master junction. #p < 0.05 vs. all conditions; ***p < 0.001 vs. all conditions. (B) Representative inverted optical microscopy images of the
formation of vessels in the in vitro angiogenesis assay on Matrigel at the final time point (3 h) (40×).
in response to endothelial activation by TNFalpha, the cells are
capable of releasing a higher number of MPs into the medium as
a result of the damage induced by the stimulus. We hypothesized
that different quantity of EMPs could act as different signaling
process between cells; in our work we focused on the interaction
of MPs with EPCs. Until now, the works only characterize the
microparticles and/or utilize cells lines well-knowns. We used
EPCs that were isolated from peripheral blood and we tried to
assess the functionally changes of these in vitro.
Our hypothesis is on the way that EMPs could carry
information to recruit EPCs from bone narrow to mobilize them
and repair the endothelial damage made by multiple factors in a
pathologies context.
EPC progression in vitro depends on the dose of MPs from
TNFalpha-stimulated endothelial cells. High doses (105MPs/ml)
attenuate the formation of CFUs in a fibronectin matrix during
25–30 days of culture. In contrast, low doses (103MPs/ml)
enhance CFU formation compared with both the control and
MP-free conditions.
Regarding the healing of an exogenously inflicted wound in
a mature endothelial cell culture, the treatment of EPCs with a
high dose of MPs (105MPs/ml) causes a loss of the cooperative
function of the EPCs in closing the wound.
Consistent with the wound closing experiment, the EPCs
treated with a high MP dose (105MPs/ml) lose some of their
ability to adhere to the mature endothelial cell monolayer.
We suggest that those EPCs treated with high doses of MPs
(105MPs/ml) lose a portion of their angiogenic potential on
mature endothelial cells and that those treated with low doses
(103MPs/ml) enhance this effect.
Of special interest is the observation that to induce a repair
response via the EPCs, the MPs must be at a low proportion
(approximately 1 MP per 100 cells), which could explain the lack
of repair activity by EPCs described in pathologies that present
significant endothelial damage or low production of EPCs.
In response to the inflammatory onslaught induced by
the cytokine TNFalpha, endothelial cells produce MPs (Alexy
et al., 2014). In agreement with previously published studies
(Mezentsev et al., 2005), when adding these MPs to EPCs, we
observe increased cell proliferation as well as an increase in the
capacity of EPCs to adhere to the damaged endothelium. The
dose-response study indicated that MPs induce proliferation and
adhesion in EPCs at relatively low doses (103MPs/ml), a dose
that is commonly observed in the plasma of healthy individuals
(Clarke et al., 2010). A reduced proliferation and adhesion of
EPCs was observed when using 105MPs/ml. We consider these
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results interesting because, until now, the use of MPs as markers
of endothelial damage has been limited to merely demonstrating
an increase in the number of these MPs in the plasma associated
with different pathologies (Chironi et al., 2009). However, our
study suggests that at least to activate the functionality of EPCs,
the number of MPs is as important as the availability of target
cells. That is, a high number of EMPs would be useful in
stimulating EPCs activity when these EMPs are in contact with
EPCs that can be mobilized, such as in a healthy individual.
However, in elderly people or during a pathological condition
in which a decreased number of EPC cells has been described
(Chang et al., 2007; Williamson et al., 2013; Castejon et al., 2014),
the same amount of EMPs would not only prevent the activity of
these cells but would also inhibit it.
The specificity of a mechanism that is dependent on the
stimulation of EPC capacity by MPs was revealed when
we demonstrated that MP-free supernatant was incapable of
inducing the proliferation and/or adhesion of EPCs.
In summary, our study identifies the MPs produced by
activated endothelial cells as intercellular signaling factors that
induce EPCs to proliferate, differentiate, adhere and regenerate
the damaged endothelium. In addition, our results suggest that
this activity is associated with the number of MP that has been
added to the target cells. When the ratio of MPs is approximately
2:100 MPs/target cells, these MPs are able to stimulate the
different competence of this cells in vitro. However, when the
MPs are approximately in ratio 1:1, occurs the opposite fact, and
the EPCs lose their abilities. In pathological conditions there is
an increase of total MPs, a decrease of circulating EPCs, or both.
Therefore, the ratio would be proportionally modified.
These results reinforce previous studies suggesting the use of
MPs as components of vascular regeneration therapy. The results
also expand the potential of MPs therapy by indicating that the
number of circulating MPs is key role in the repair activity of
EPCs; thus, new potential therapeutic strategies could be directed
at decreasing the elevated number of circulating MPs that has
been described in patients with vascular disease.
Our study could provide a foundation for designing possible
therapeutic strategies utilizing MPs as activating factors in
vascular repair and regeneration, taking into accounts the
population of circulating EPCs in pathological conditions and the
specific expression of MPs in these same pathologies.
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